Transgenic Factor VII Purification via Affinity Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying recombinant human activated Factor VII from transgenic sources are inefficient, leading to products with residual coagulation factors, viral and bacterial contamination risks, and limited plasma volume, while also struggling to completely remove native proteins from transgenic mammals that can trigger immunogenicity in humans.
Innovation Solution
A multi-step purification method involving affinity chromatography with a specific antigen-binding protein, followed by ion exchange, pseudo-affinity, and size exclusion chromatography, along with viral inactivation steps, to produce highly purified and activated Factor VII free from aggregates and degraded forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If plasma fractionation methods are used to obtain FVIIa concentrates, then some FVIIa can be purified, but the product contains residual traces of other coagulation factors and shows residual thrombogenic activity
Solution Approach 1:
The patent extracts and removes specific harmful components (other coagulation factors, thrombogenic substances) from the FVIIa preparation using selective purification steps including affinity chromatography with specific ligands that bind to and remove contaminating proteins while allowing FVIIa to pass through
Solution Approach 2:
The patent introduces intermediary substances (specific affinity ligands, chromatography resins) that mediate the separation process by selectively interacting with harmful contaminants while leaving FVIIa unaffected, enabling precise removal of impurities without losing the desired protein
2Reliability
If conventional purification processes are used, then some viral and bacterial safety measures can be implemented, but risks of contamination with pathogenic agents remain and volume of plasma collected is limited
Solution Approach 1:
The patent uses transgenic animals as biological copies that produce human FVIIa in their milk, replacing the need to process large volumes of human plasma. The transgenic animals are genetically engineered to express the human factor, creating a source that is both safe (animal-derived) and sufficient in quantity
Solution Approach 2:
The patent changes the source parameter from human plasma to transgenic animal milk, fundamentally altering the material origin. This parameter change enables both high quantity production (milk is abundant) and high reliability (animal-based production allows for controlled, consistent supply with reduced pathogen risk
3Quantity of substance
If transgenic mammals are used to produce FVII, then quantity of product can be increased, but native proteins from transgenic mammals remain and can trigger immunogenicity in humans
Solution Approach 1:
The patent removes native animal proteins from the transgenic milk using affinity chromatography with species-specific ligands that bind to and extract host proteins while allowing the human FVIIa to pass through, achieving high purity despite the transgenic source
Solution Approach 2:
The patent introduces intermediary affinity ligands that mediate the separation between the desired human FVIIa and harmful native animal proteins. These ligands specifically interact with animal proteins through their animal-specific epitopes, enabling selective removal without affecting the human factor
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high purity and activation of Factor VII, significantly reducing residual contaminants and viral loads, ensuring safety and efficacy by eliminating immunogenic native proteins and pathogenic agents, while optimizing the use of transgenic sources.
Implementation Method 1
a step of affinity chromatography comprising the steps of: i. contacting the milk containing human TgFVII and/or human TgFVIIa with a ligand which is specific to human TgFVII and/or human TgFVIIa, under conditions allowing the human TgFVII and/or human TgFVIIa to bind the ligand
Implementation Method 2
b) chromatographic purification of the eluted human TgFVII and /or human TgFVIIa on an ion exchanger
Implementation Method 3
d) chromatographic separation of the eluted human TgFVII and/or human TgFVIIa on a size exclusion support
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to an anti-Factor VII affinity ligand that is particularly useful for purifying recombinant human activated Factor VII from transgenic sources. The affinity ligand combined with other orthogonal chromatographic steps allows the preparation of a highly purified FVII solution fully activated free of aggregates with a low percentage of degraded or oxidized FVII forms.